Endocrine Society GUIDELINES Bundle (free trial)

Lipid Management in Endocrine Disorders

Endocrine Society GUIDELINES Apps brought to you free of charge courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1356565

Contents of this Issue

Navigation

Page 6 of 21

7 Table 3. Proposed Decision-Making Approach to Selective Use of CAC Measurement for Risk Prediction Using 10-year ASCVD Risk Estimate plus CAC Score to Guide Statin Therapy Patient's 10-year ASCVD risk estimate <5% 5%–7.4% 7.5%–19.9% ≥20% Consulting ASCVD risk estimate alone Statin not recommended Consider statin Recommend statin Recommend statin Consulting ASCVD risk estimate + CAC If CAC score = 0 Statin not recommended Statin generally not recommended Statin generally not recommended Recommend statin If CAC score >0 Statin may be considered Recommend statin Recommend statin Recommend statin Does CAC score modify treatment plan? × CAC less effective for this population ✔ CAC can reclassify risk up or down ✔ CAC can reclassify risk up or down × CAC not effective for this population Note: CAC = 0 should not be used as sole justification for use of lifestyle alone, to the exclusion of pharmacotherapy in familial hyper-cholesterolemia, advanced diabetes, and/or active smoking. Source: From Greenland P, Blaha MJ, Budoff MJ, Erbel R, Watson KE. "Coronary Calcium Score and CV Risk." J Am Coll Cardiol. 2018; 72(4): 434-447.

Articles in this issue

Archives of this issue

view archives of Endocrine Society GUIDELINES Bundle (free trial) - Lipid Management in Endocrine Disorders